Some patients with stage III melanoma can avoid surgery after neoadjuvant immunotherapy
CHICAGO — Tumor lymph node dissection likely can be omitted for patients with melanoma who achieve major pathologic response after neoadjuvant immune checkpoint blockade, according to study results presented at ASCO Annual Meeting.Patients who achieve major pathologic response do not need adjuvant systemic therapy; however, adjuvant systemic therapy appears to extend survival for patients